CRISPR Therapeutics AG (CRSP)
54.07
-0.16
(-0.30%)
USD |
NASDAQ |
Sep 28, 16:00
54.07
0.00 (0.00%)
After-Hours: 16:40
CRISPR Therapeutics Research and Development Expense (TTM) : 263.69M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 263.69M |
| March 31, 2026 | 264.04M |
| December 31, 2025 | 265.41M |
| September 30, 2025 | 264.86M |
| June 30, 2025 | 287.72M |
| March 31, 2025 | 297.74M |
| December 31, 2024 | 301.33M |
| September 30, 2024 | 314.26M |
| June 30, 2024 | 322.68M |
| March 31, 2024 | 343.95M |
| December 31, 2023 | 367.50M |
| September 30, 2023 | 374.96M |
| June 30, 2023 | 439.65M |
| March 31, 2023 | 492.93M |
| December 31, 2022 | 540.90M |
| September 30, 2022 | 571.40M |
| June 30, 2022 | 520.93M |
| March 31, 2022 | 475.74M |
| December 31, 2021 | 420.75M |
| September 30, 2021 | 372.34M |
| June 30, 2021 | 341.01M |
| Date | Value |
|---|---|
| March 31, 2021 | 293.52M |
| December 31, 2020 | 257.75M |
| September 30, 2020 | 225.28M |
| June 30, 2020 | 212.57M |
| March 31, 2020 | 194.92M |
| December 31, 2019 | 176.65M |
| September 30, 2019 | 158.12M |
| June 30, 2019 | 141.98M |
| March 31, 2019 | 128.08M |
| December 31, 2018 | 113.77M |
| September 30, 2018 | 105.00M |
| June 30, 2018 | 83.03M |
| March 31, 2018 | 74.51M |
| December 31, 2017 | 69.80M |
| September 30, 2017 | 65.34M |
| June 30, 2017 | 59.55M |
| March 31, 2017 | 51.03M |
| December 31, 2016 | 42.24M |
| September 30, 2016 | 28.15M |
| June 30, 2016 | 17.26M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.907B |
| Basilea Pharmaceutica AG | 153.18M |
| Santhera Pharmaceuticals Holding AG | 26.72M |
| BeOne Medicines Ltd. | 2.220B |
| Intellia Therapeutics, Inc. | 337.63M |